These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 28314656)

  • 1. Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus.
    Gómez-Huelgas R; Sabán-Ruiz J; García-Román FJ; Quintela-Fernández N; Seguí-Ripoll JM; Bonilla-Hernández MV; Romero-Meliá G
    Rev Clin Esp (Barc); 2017 May; 217(4):201-206. PubMed ID: 28314656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].
    Zďarská DJ; Brož J; Křivská B; Rušavý Z; Kvapil M
    Vnitr Lek; 2014 Sep; 60(9):712-9. PubMed ID: 25294758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Hypoglycaemia in Patients with Type 2 Diabetes - A Subgroup Analysis from the GINGER study.
    Fritsche A; Hahn A; Landgraf W; Häring HU
    Eur Endocrinol; 2013 Mar; 9(1):1-3. PubMed ID: 30349602
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective].
    Jermendy G; Kovács G
    Orv Hetil; 2018 Dec; 159(50):2122-2128. PubMed ID: 30545262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose.
    Kress S; Borck A; Zisman A; Bramlage P; Siegmund T
    Diabetes Metab Syndr Obes; 2021; 14():1215-1222. PubMed ID: 33776458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus.
    Choe EY; Lee YH; Lee BW; Kang ES; Cha BS; Lee HC
    Diabetes Metab J; 2012 Jun; 36(3):230-6. PubMed ID: 22737663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen].
    Efremova NV; Bolotskaya LL; Atarshchikov DS; Bondarenko ON; Ilyin AV; Shestakova MV
    Ter Arkh; 2015; 87(10):42-49. PubMed ID: 26978173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal-Bolus Insulin: Phase 4 OPTIMIZE Study.
    Mathieu C; Weisnagel SJ; Stella P; Bruhwyler J; Alexandre K
    Diabetes Ther; 2020 Feb; 11(2):495-507. PubMed ID: 31925722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.
    Jin Y; Sun X; Zhao X; Zhu T
    Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA.
    Bueno E; Benitez A; Rufinelli JV; Figueredo R; Alsina S; Ojeda A; Samudio S; Cáceres M; Argüello R; Romero F; Echagüe G; Pasquel F; Umpierrez GE
    Endocr Pract; 2015 Jul; 21(7):807-13. PubMed ID: 26121460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
    Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
    Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPARISON OF BASAL INSULIN REGIMENS ON GLYCEMIC VARIABILITY IN NONCRITICALLY ILL PATIENTS WITH TYPE 2 DIABETES.
    Haw JS; Farrokhi F; Smiley D; Peng L; Reyes D; Newton C; Pasquel FJ; Vellanki P; Umpierrez GE
    Endocr Pract; 2015 Dec; 21(12):1333-43. PubMed ID: 26307899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
    Tonneijck L; Muskiet MHA; Twisk JW; Kramer MHH; Danser AHJ; Joles JA; Smits MM; van Raalte DH
    Hypertension; 2018 Aug; 72(2):314-322. PubMed ID: 29915021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study.
    Pfohl M; Seufert J; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):733-747. PubMed ID: 33544355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.